Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosesimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGreat news! On May 18, Bio-Thera's recombinant humanized anti-VEGF monoclonal antibody injection (BAT1706 ) was approved for clinical trials by the China Food and Drug Administration (CFDA), marking our second approval for biosesimilar clinical trials this year. BAT1706 is a bevacizumab biosesimilar ind...
On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706 (a bevacizumab biosesimilar), which is currently carrying out its global development plan, has enrolled its first two healthy subjects in New Zealand. This is the first clinical ...
